A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
- Summary
- This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medicine. Doctors cannot yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide. Doctors can prescribe tirzepatide in some countries. Participants will either receive CagriSema or tirzepatide. Which treatment the participant will receive is decided by chance. For each participant, the study will last for up to 1 year and 4 months.
- Acronym
- REIMAGINE 5
- Short title
- A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
- Official title
- Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 1.0 mg/1.0 mg s.c. Once Weekly Versus Tirzepatide 5 mg s.c. Once Weekly in Participants With Type 2 Diabetes Inadequately Controlled on Metformin, SGLT2 Inhibitor or Both
- Control arm
- Open label
- Registry reports results
- Listing at source
- Listed
- Recruitment status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Completion date
- 2026-07-09
- First posted
- 2024-08-02
- Registry last updated
- 2026-07-17
- Primary completion date
- 2026-06-02
- Start date
- 2024-11-05
- Actual participants
- 1,023
- Participants
- 1,023
- Participant count basis
- Actual
- Protocol amendments
- Number of sites
- Data monitoring committee
- Registry sponsor category
- Industry
- Lead sponsor
- Novo Nordisk A/S
- Source registry
- ClinicalTrials.gov
- Registry ID
- NCT06534411
- ClinicalTrials.gov ID
- NCT06534411
- Registry record
- Open registry record
- Allocation
- Randomised
- Model
- Parallel groups
- Purpose
- Treatment
- Masking
- No masking
Change in Glycated Haemoglobin (HbA1c)
Timeframe: From baseline (week 0) to end of treatment (week 60)
Measured in percentage points.
Relative Change in Body Weight
Timeframe: From baseline (week 0) to end of treatment (week 60)
Measured in percentage (%).
Change in HbA1c
Timeframe: From baseline (week 0) to end of treatment (week 60)
Measured in percentage points.
Change in Fasting Plasma Glucose (FPG)
Timeframe: From baseline (week 0) to end of treatment (week 60)
Measured as millimole per liter (mmol/L).
Number of Participants Who Achieve HbA1c Target Values of Less Than (<) 7.0 (Percent [%]) (< 53 millimole per mole [mmol/mol])
Timeframe: At end of treatment (week 60)
Measured as count of participants.
Number of Participants Who Achieve HbA1c Target Values of Less Than or Equal to (<=) 6.5% (<= 48 mmol/mol)
Timeframe: At end of treatment (week 60)
Measured as count of participants.
Number of Participants Who Achieve Greater Than or Equal to (>=) 5% Weight Reduction
Timeframe: From baseline (week 0) to end of treatment (week 60)
Measured as count of participants.
Number of Participants Who Achieve >= 10% Weight Reduction
Timeframe: From baseline (week 0) to end of treatment (week 60)
Measured as count of participants.
Number of Participants Who Achieve >= 15% Weight Reduction
Timeframe: From baseline (week 0) to end of treatment (week 60)
Measured as count of participants.
Number of Participants Who Achieve >= 20% Weight Reduction
Timeframe: From baseline (week 0) to end of treatment (week 60)
Measured as count of participants.
Change in Systolic Blood Pressure (SBP)
Timeframe: From baseline (week 0) to end of treatment (week 60)
Measured in millimeter of mercury (mmHg).
Change in Diastolic Blood Pressure (DBP)
Timeframe: From baseline (week 0) to end of treatment (week 60)
Measured in mmHg.
Change in Waist Circumference
Timeframe: From baseline (week 0) to end of treatment (week 60)
Measured in centimeter (cm).
Ratio to Baseline in Lipids: Total Cholesterol
Timeframe: From baseline (week 0) to end of treatment (week 60)
Measured as ratio.
Ratio to Baseline in Lipids: High Density Lipoprotein (HDL) Cholesterol
Timeframe: From baseline (week 0) to end of treatment (week 60)
Measured as ratio.
Ratio to Baseline in Lipids: Low Density Lipoprotein (LDL) Cholesterol
Timeframe: From baseline (week 0) to end of treatment (week 60)
Measured as ratio.
Ratio to Baseline in Lipids: Very Low Density Lipoprotein (VLDL) Cholesterol
Timeframe: From baseline (week 0) to end of treatment (week 60)
Measured as ratio.
Ratio to Baseline in Lipids: Triglycerides
Timeframe: From baseline (week 0) to end of treatment (week 60)
Measured as ratio.
Ratio to Baseline in Lipids: Non-HDL cholesterol
Timeframe: From baseline (week 0) to end of treatment (week 60)
Measured as ratio.
Change in Short Form (SF) -36v2 Score: Physical Component Summary Score
Timeframe: From baseline (week 0) to end of treatment (week 60)
Measured as score points. SF-36v2 Acute measures Health-Related Quality of Life (HRQOL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2. Acute scores are norm-based scores, i.e. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Physical component summary scores ranges from 6.1 to 79.7 with higher scores indicating better functional health and well-being.
Change in SF-36v2 Score: Mental Component Summary Score
Timeframe: From baseline (week 0) to end of treatment (week 60)
Measured as score points. SF-36v2 Acute measures Health-Related Quality of Life (HRQOL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2. Acute scores are norm-based scores, i.e. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Mental component summary scores ranges from -3.8 to 78.7 with higher scores indicating better functional health and well-being.
Change in SF-36v2 Score: Vitality Subscale
Timeframe: From baseline (week 0) to end of treatment (week 60)
Measured as score points. SF-36v2 Acute measures Health-Related Quality of Life (HRQOL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2. Acute scores are norm-based scores, i.e. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Vitality score ranges from 25.6 to 69.1 with higher scores indicating better functional health and well-being.
Change in Impact of Weight on Quality of Life Lite for Clinical Trials Version (IWQOL-Lite-CT) : Physical Function score
Timeframe: From baseline (week 0) to end of treatment (week 60)
Measured as score points. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. Physical functioning score ranges from 0 to 100, with higher scores reflecting better levels of functioning.
Change in IWQOL-Lite-CT: Total score
Timeframe: From baseline (week 0) to end of treatment (week 60)
Measured as score points. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. Total score ranges from 0 to 100, with higher scores reflecting better levels of functioning.
Number of Treatment Emergent Adverse Events (TEAEs)
Timeframe: From baseline (week 0) to end of study (week 66)
Measured as count of events.
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (<54 Milligram per Deciliter [mg/dL]), Confirmed by Blood Glucose (BG) Meter
Timeframe: From baseline (week 0) to end of study (week 66)
Measured as count of episodes.
Number of Severe Hypoglycaemic Episodes (Level 3): Hypoglycaemia Associated With Severe Cognitive Impairment Requiring External Assistance for Recovery, With no Specific Glucose Threshold
Timeframe: From baseline (week 0) to end of study (week 66)
Measured as count of episodes.
- Sex
- All
- Age groups
- Adults, Older adults
- Minimum age
- 18 Years
- Healthy volunteers
- No
- Male or female (sex at birth).
- Age 18 years or above at the time of signing the informed consent.
- Diagnosed with type 2 diabetes mellitus greater than or equal to (>=) 180 days before screening.
- Stable daily dose(s) >= 90 days before screening of any of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator:
- Metformin
- sodium-glucose co-transporter 2 inhibitor (SGLT2i)
- Glycated haemoglobin (HbA1c) 7.0-10.5 percent (53-91 millimoles per mol [mmol/mol]) (both inclusive) as determined by central laboratory at screening.
- Body mass index (BMI) >= 30 kilogram per square meter (kg/m^2) at screening. BMI will be calculated in the electronic case report form (eCRF) based on height and body weight at screening.
- Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using a highly effective contraceptive method.
- Renal impairment with estimated Glomerular Filtration Rate less than < 30 milliliter per minute per 1.73 square meter (mL/min/1.73 m^2) as determined by central laboratory at screening.
- Treatment with any anti-diabetic or anti-obesity medication (irrespective of indication) other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days is allowed.
- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
- Cahaba ResearchPelham, United States
- Velocity Clinical Research-PhoenixPhoenix, United States
- AES Tucson DRSTucson, United States
- Woodland Int. Research GroupLittle Rock, United States
- Velocity Clin Res-Chula VistaChula Vista, United States
- John Muir Physicians NetworkConcord, United States
- Diabetes & Endocrine Specialists - La MesaLa Mesa, United States
- Velocity Clin Research LALos Angeles, United States
- Desert Oasis HealthcarePalm Springs, United States
- Velocity Clin Res Santa AnaSanta Ana, United States
- Velocity Clin Res - PanoramaVan Nuys, United States
- Optumcare Clinical Trials,LLC-GoldenColorado Springs, United States
- FEME Medical LLCWashington D.C., United States
- Tampa Bay Medical ResearchClearwater, United States
- AGA Clinical TrialHialeah, United States
- Bioclinical Research AllianceMiami, United States
- New Horizon Research CenterMiami, United States
- South Broward Research LLCMiramar, United States
- West Orange EndocrinologyOcoee, United States
- Optimal Research SitesOrange City, United States
- Center for Diab,Obes & MetabPembroke Pines, United States
- Javara Inc. / Privia Medical Group Georgia LLCFayetteville, United States
- Clinical Invest Special_GurneeGurnee, United States
- Iowa Diabetes & Endo Res CtrWest Des Moines, United States
- Cotton-Oneill Diabetes and EndTopeka, United States
And 138 more, listed on the interactive page.
- 2023
- 2023-509600-15
- U1111-1300-2590
Related records
Drugs (3)
Lead sponsors (1)
Conditions (1)
- Type 2 diabetes mellitus Primary condition